Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

The Phage raises ¥570 million in Series A funding led by Itochu Technology Ventures to develop AI blood glucose prediction technology. The company also forms strategic alliance with Tokio Marine Holdings.

PRIVATEOct 13, 2026

Amount Raised

¥570 Million

Round Type

Series A

BiotechnologyHealth Care

Investors

Shoko Chukin BankVision IncubateGenesia VenturesFukui Capital PartnersTokio Marine & Nichido Fire InsuranceItochu Technology Ventures

Description

The Phage, a developer of AI-powered continuous glucose foundation models (CGFM), announced it has raised ¥570 million through a Series A 1st round equity allocation and loans. The round was led by Itochu Technology Ventures, with new investors Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners, alongside returning investors Genesia Ventures and Vision Incubate. The Shoko Chukin Bank provided loan financing. Additionally, The Phage established a capital and business alliance with Tokio Marine Holdings to commercialize healthcare solutions for lifestyle-related disease prevention.

Company Information

Company

The Phage

About

The Phage is engaged in research and development of a blood glucose foundation model (CGFM) that learns from continuous blood glucose data to predict postprandial blood glucose fluctuations using AI. The company has developed Glucose Flight, a service that supports daily dietary management by evaluating meal content based on blood glucose fluctuations. They collaborate with healthcare institutions and local governments to offer blood glucose management programs aimed at preventing lifestyle-related diseases. The company is transitioning from research and demonstration phases to commercial-scale operations.

Fundz sees it the moment The Phage raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for The Phage's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

The Phage raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.